Log in to save to my catalogue

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2902937164

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Among patients with previously untreated chronic lymphocytic leukemia, ibrutinib–venetoclax therapy with treatment duration guided by measurable residual disease status resulted in better outcomes than standard chemotherapy.

Alternative Titles

Full title

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2902937164

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2902937164

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2310063

How to access this item